IBI-395

N/A

Report date: 2022/01/17 17:29:35

Base Information

Drug NameIBI-395

Drug Alias NameIBI-395

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProgrammed cell death protein 1 blockersInterleukin 21 Receptor agonistsInterleukin-2 receptor agonists

TargetsProgrammed cell death protein 1Interleukin 21 ReceptorInterleukin-2 receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInnovent Biologics(Suzhou) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A